AG-490 (Tyrphostin B42)

Name: AG-490 (Tyrphostin B42)
Brand: Selleck Chemicals
SKU: S1143
Rating: 5 (91 reviews)

For research use only.

Catalog No.S1143 Synonyms: Zinc02557947

91 publications

AG-490 (Tyrphostin B42) Chemical Structure

CAS No. 133550-30-8

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.

Selleck's AG-490 (Tyrphostin B42) has been cited by 91 publications

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(18):18084-18098

PubMed: 32957082 ( click the link to review the publication )

Carcinogenesis, 2020, 41(7):993-1004

PubMed: 31740922 ( click the link to review the publication )

Oncogenesis, 2020, 10;9(2):15

PubMed: 32041943 ( click the link to review the publication )

Front Pharmacol, 2020, 26;11:273

PubMed: 32273843 ( click the link to review the publication )

Food Funct, 2020, 11(5):3941-3951

PubMed: 32338270 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):632

PubMed: 32641093 ( click the link to review the publication )

Mol Cells, 2020, 43(8):749-762

PubMed: 32868491 ( click the link to review the publication )

Exp Biol Med (Maywood), 2020, 245(7):654-666

PubMed: 32075431 ( click the link to review the publication )

J Appl Toxicol, 2020, 24

PubMed: 32212198 ( click the link to review the publication )

Connect Tissue Res, 2020, 5;1-16

PubMed: 32370570 ( click the link to review the publication )

J Interferon Cytokine Res, 2020, 40(2):116-124

PubMed: 31834821 ( click the link to review the publication )

Pharmazie, 2020, 75(6):255-260

PubMed: 32539921 ( click the link to review the publication )

Arch Biochem Biophys, 2020, 685:108330

PubMed: 32156533 ( click the link to review the publication )

Cell Prolif, 2020, 53(8):e12856

PubMed: 32648622 ( click the link to review the publication )

Mol Med Rep, 2020, 21(1):89-96

PubMed: 31746349 ( click the link to review the publication )

Virus Res, 2020, 281:197907

PubMed: 32113834 ( click the link to review the publication )

J Cancer, 2020, 11(16):4771-4782

PubMed: 32626524 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(2):360-367

PubMed: 31668806 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 2020:9187406

PubMed: 32832009 ( click the link to review the publication )

J Surg Res, 2020, 248:98-108

PubMed: 31877436 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 524(4):963-969

PubMed: 32059851 ( click the link to review the publication )

Anim Biotechnol, 2020, 1-13

PubMed: 32657254 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )
Aging (Albany NY), 2019, 11(17):6674-6690

PubMed: 31481647 ( click the link to review the publication )

J Cell Physiol, 2019, 234(9):15395-15406

PubMed: 30710340 ( click the link to review the publication )

J Cell Physiol, 2019, 234(11):21182-21192

PubMed: 31032948 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(9):1882-1891

PubMed: 31523190 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:57

PubMed: 30918473 ( click the link to review the publication )

Front Pharmacol, 2019, 10:620

PubMed: 31231218 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 362:59-66

PubMed: 30352208 ( click the link to review the publication )

Eur J Pharmacol, 2019, 854:289-297

PubMed: 31004602 ( click the link to review the publication )

Oral Dis, 2019, 25(7):1769-1779

PubMed: 31365165 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

J Cell Physiol, 2018, 234(1):454-463

PubMed: 29932210 ( click the link to review the publication )

Mol Carcinog, 2018, 57(3):429-439

PubMed: 29215754 ( click the link to review the publication )

Biomed Pharmacother, 2018, 101:107-114

PubMed: 29477470 ( click the link to review the publication )

Int J Oncol, 2018, 52(5):1515-1527

PubMed: 29512698 ( click the link to review the publication )

Toxicology, 2018, 408:62-69

PubMed: 29981841 ( click the link to review the publication )

Am J Transl Res, 2018, 10(2):465-473

PubMed: 29511440 ( click the link to review the publication )

Eur J Pharmacol, 2018, 833:221-229

PubMed: 29890157 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Biomed Res Int, 2018, 2018:2548378

PubMed: 30363706 ( click the link to review the publication )

Neurosci Lett, 2018, 662:219-226

PubMed: 29061394 ( click the link to review the publication )

Oncol Lett, 2018, 16(2):2517-2524

PubMed: 30013646 ( click the link to review the publication )

Int Urol Nephrol, 2018, 50(8):1535-1544

PubMed: 29508174 ( click the link to review the publication )

Antioxid Redox Signal, 2017, 27(5):251-268

PubMed: 27923278 ( click the link to review the publication )

Cardiovasc Res, 2017, 113(3):310-320

PubMed: 28158495 ( click the link to review the publication )
Cell Physiol Biochem, 2017, 44(1):293-302

PubMed: 29132131 ( click the link to review the publication )

Int J Mol Sci, 2017, 18(12)

PubMed: 29206176 ( click the link to review the publication )

Am J Transl Res, 2017, 9(10):4617-4626

PubMed: 29118922 ( click the link to review the publication )

Brain Res, 2017, 15;1657:202-207

PubMed: 27998796 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:2787-2799

PubMed: 29033541 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169665

PubMed: 28068414 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5329-5336

PubMed: 29184419 ( click the link to review the publication )

Cell Biol Int, 2017, 41(6):659-668

PubMed: 28378938 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:2942830

PubMed: 28630633 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96993-97008

PubMed: 29228588 ( click the link to review the publication )

Oncotarget, 2017, 8(57):96958-96969

PubMed: 29228585 ( click the link to review the publication )

Oncotarget, 2017, 8(39):64853-64866

PubMed: 29029396 ( click the link to review the publication )

Oncotarget, 2017, 8(28):45848-45861

PubMed: 28507278 ( click the link to review the publication )

Oncogene, 2016,

PubMed: 26804171 ( click the link to review the publication )

PLoS Pathog, 2016, 12(4):e1005605

PubMed: 27128969 ( click the link to review the publication )

Stem Cells Transl Med, 2016, 5(7):960-9

PubMed: 27130223 ( click the link to review the publication )

Clin Exp Immunol, 2016, 184(2):147-58

PubMed: 26646950 ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Inflamm Res, 2016, 65(3):193-202

PubMed: 26621504 ( click the link to review the publication )

Int J Mol Med, 2016, 38(4):1125-34

PubMed: 27599586 ( click the link to review the publication )

J Bone Miner Metab, 2016, [Epub ahead of print]

PubMed: 27628046 ( click the link to review the publication )

Scand J Immunol, 2016,

PubMed: 26482544 ( click the link to review the publication )

Mol Med Rep, 2016, 13(4):3684-90

PubMed: 26936086 ( click the link to review the publication )

Oncotarget, 2016, 7(27):41445-41459

PubMed: 27213590 ( click the link to review the publication )
Cancer Lett, 2015, 359(2):335-43

PubMed: 25641338 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: 25411359 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):142-50

PubMed: ( click the link to review the publication )

Neoplasia, 2015, 17(8):625-33

PubMed: 26408255 ( click the link to review the publication )

Eur Neuropsychopharmacol, 2015, 25(8):1287-99

PubMed: 25979764 ( click the link to review the publication )

Eur Neuropsychopharm, 2015, 10.1016/j.euroneuro.2015.04.020

PubMed: ( click the link to review the publication )

Int J Neuropsychopharmacol, 2015, 19(2)

PubMed: 26438799 ( click the link to review the publication )

Oncol Rep, 2015, 34(4):1875-82

PubMed: 26238612 ( click the link to review the publication )

J Geriatr Cardiol, 2015, 12(6):591-9

PubMed: 26788034 ( click the link to review the publication )

Mol Cancer, 2014, 13:176

PubMed: 25047660 ( click the link to review the publication )

Carcinogenesis, 2014, 35(4):795-806

PubMed: 24265293 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2014, 307(7):C597-605

PubMed: 24944200 ( click the link to review the publication )

Oncotarget, 2014, 5(16):7051-64

PubMed: 25216522 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(17):4697-705

PubMed: 23857601 ( click the link to review the publication )

Cancer Lett, 2013, 341(2):224-30

PubMed: 23941832 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 429(3-4):156-62

PubMed: 23142594 ( click the link to review the publication )

Biochem Biophys Res Commun, 2013, 435(4):533-9

PubMed: 23665018 ( click the link to review the publication )

Prostate, 2012, 73(3):267-77

PubMed: 22821817 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Targets

JAK2 (V617F) ^[8] ()	EGFR ^[1] (Cell-free assay)
	0.1 μM

In vitro

AG-490 inhibits HER-2 driven cell proliferation with IC50 of 3.5 μM. ^[1] Corresponding to the specific dose-dependent inhibition of constitutively activated JAK2 in pre-B acute leukemia (ALL) cells, AG-490 (5 μM) almost completely blocks the growth of all ALL cells by inducing programmed cell death, with no deleterious effect on normal hematopoiesis. AG-490 does not inhibit the activities of Lck, Lyn, Btk, Syk, and Src. ^[2] AG-490 (60-100 μM) blocks the constitutive activation of Stat3sm, and inhibits spontaneous as well as interleukin 2-induced growth of mycosis fungoides (MF) tumor cells with IC50 values of 75 μM and 20 μM, respectively. ^[3] AG-490 potently inhibits IL-2-mediated human T cell growth with an IC50 of 25 μM by blocking the activities of JAK3 and STAT5a/b. ^[4] Although AG-490 alone has no effect on proliferation of FDrv210H cells at a concentration of 5 μM, AG-490 can synergize with STI571 to enhance its inhibitory effect on p210^bcr-abl driven proliferation. ^[5] AG-490 significantly inhibits the constitutive activation of Stat3 in MOPC, MPC11, and S194 cells, leading to dramatic dose-dependent apoptosis. ^[6] AG-490 (100 μM) inhibits Akt phosphorylation, inhibits the activation of nuclear factor-κB, and causes the activation of GSK-3β, leading to the reduction of c-Myc. AG-490 (50 μM) can induce apoptosis of imatinib-resistant BaF3 cells expressing T315I and E255K mutants of Bcr-Abl. ^[7] AG-490 at 30 μM inhibits not only Epo-induced phosphorylation of wild-type JAK2 but also constitutive phosphorylation of the JAK2 V617F mutant. AG-490 also potently inhibits cytokine-independent cell growth induced by the JAK2 V617F mutant in BaF3 cells. ^[8]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
BC3	NHPhSXlHfW6ldHnvckBCe3OjeR?=	MUOxNFDjiIoEtV2=	Ml7ZNlQhcA>?		MXnt[YRq[XSnczDQSWwh[2WubDDhdI9xfG:\|aYO=	MWqyOlE5PDl7OR?=
BCBL1	NXG5U3EzTnWwY4Tpc44hSXO\|YYm=	M3PEflExOOLCidM1US=>	NXzZcIJHOjRiaB?=		NU\RZW94dWWmaXH0[ZMhWEWOIHPlcIwh[XCxcITvd4l{	MojqNlYyQDR7OUm=
BC3	NWnR[GNmTnWwY4Tpc44hSXO\|YYm=	M3;lb\|ExOOLCidM1US=>	NHfB[oQzPCCq		MkTZcYVlcWG2ZYOg[IUueGixc4Doc5J6dGG2aX;uJI9nKFOWQWSzJINwenKnbHH0[YQhf2m2aDDIV3A4OCCjbnSgTHNHOSC{ZXT1Z5Rqd25?	M3rQZ\|I3OTh2OUm5
BCBL1	MXzGeY5kfGmxbjDBd5NigQ>?	MV2xNFDjiIoEtV2=	NX7HbmRlOjRiaB?=		MWnt[YRq[XSnczDk[U1xcG:\|cHjvdplt[XSrb36gc4YhW1SDVEOgZ49zemWuYYTl[EB4cXSqIFjTVFcxKGGwZDDIV2YzKHKnZIXjeIlwdg>?	M4HlU\|I3OTh2OUm5
BC3	MUDGeY5kfGmxbjDBd5NigQ>?	NYHDOVZqOTBy4pEJxtVO	MUGyOEBp		M3zESolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKG[udYlCpC=>	M{LabVI3OTh2OUm5
BCBL1	M1Pi[2Z2dmO2aX;uJGF{e2G7	NX35TWZ1OTBy4pEJxtVO	NXTnWGEzOjRiaB?=		NEHRSm9qdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yCobIX4xsA>	MnzXNlYyQDR7OUm=
SK-MEL-28	NH3DZlVHfW6ldHnvckBCe3OjeR?=	M{nhXlUxNzFyMPMAjeK2VQ>?	M33xclQ5KGh?	MUHEUXNQ	NEnucI5z\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=>	MXKyOVIyPjV{Mh?=
MeWo	MVPGeY5kfGmxbjDBd5NigQ>?	MVq1NE8yODEkgJpCuW0>	M{D3V\|Q5KGh?	NYrLbYFiTE2VTx?=	M2DzZZJm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl	MoDoNlUzOTZ3MkK=
SK-MEL-5	NUj5clRlTnWwY4Tpc44hSXO\|YYm=	NX3Zb5pNPTBxMUCw5qCKyrWP	NWPUNo42PDhiaB?=	M{C3OWROW09?	NUfu[G9PemWmdXPld{Bidm:ra3nzJJJme2m\|dHHuZ4U>	M371UFI2OjF4NUKy
SK-MEL-2	M1TqWmZ2dmO2aX;uJGF{e2G7	NV\YW3ZSPTBxMUCw5qCKyrWP	MmPEOFghcA>?	NELzUlZFVVOR	M2rZe5Jm\HWlZYOgZY5wcWurczDy[ZNqe3SjbnPl	NHSyW3YzPTJzNkWyNi=>
B16-F0	MXzGeY5kfGmxbjDBd5NigQ>?	MlvpOVAwOTBy4pEJxtVO	NEnFemU1QCCq	NHTHbY9FVVOR	NGfLeoRz\WS3Y3XzJIFvd2mtaYOgdoV{cXO2YX7j[S=>	NHTmfJIzPTJzNkWyNi=>
TRPM2/HEK	NFzXWVZHfW6ldHnvckBCe3OjeR?=	NFX3dYkxNjIkgKOyOeKhyrWP	MWSxOeKhdWmw	MV;EUXNQ	MXfy[YR2[2W\|IFiyU\|IucW6mdXPl[EBE[TJtaX7jdoVie2ViaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJuIHHu[EB1cGViSVO1NOKhfmGudXWge4F{KDFwN9MgxtVO	NV7tZnFzOjVzN{m1O\|Q>
U937	NFv4NZNHfW6ldHnvckBCe3OjeR?=	NInZT5cxNjIkgKOyOeKhyrWP	M3LSXlE2yqCvaX6=	NUnOUWZsTE2VTx?=	NYq2OHBKemWmdXPld{BJOk9{LXnu[JVk\WRiQ3GyL4lv[3KnYYPlJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyMEBidmRidHjlJGlEPTEEoI\hcJVmKHejczCwMlTDqML3TR?=	MlHJNlUyPzl3N{S=
TRPM2/HEK	M{nKNmZ2dmO2aX;uJGF{e2G7	NH6zXncyOMLiwsXN	NWHKeFN2PDEEoH3pci=>	Mn2xSG1UVw>?	MoH0doVlfWOnczDUVnBOOiCjY4TpeoF1cW:wIHX2[Y4h[XRiaHnnbEBkd26lZX70doF1cW:wczDv[kBJOk9{	MXSyOVE4QTV5NB?=
GL37	MlT1R4VtdCCYaXHibYxqfHliQYPzZZk>	MmXLNE0yOMLiwsXN	NWrJRWw1PDhiaB?=		NEm1bJJ{fXCycnXzd4V{KEyjIHX4dJJme3Orb36=	M3rpdFI1QTl7NkW3
NRK-52E	MmnLSpVv[3Srb36gRZN{[Xl?	MVyxxsDDvU1?	NYjLdW1VOTBibXnu		NFi5[HpjdG:la4OgeIhmKHO2aX31cIF1d3K7IHXm[oVkfCCxZjDBcochUUlib36gVIF5NTJiZYjwdoV{e2mxbtMg	NFHOflIzPDdzMESyNy=>
NRK-52E	M{HMT2Z2dmO2aX;uJGF{e2G7	MoK4NeKhyrWP	MVqxNEBucW5?		M2ewWYJtd2OtczDBcochUUliaX7keYNm\CCFREK0JIV5eHKnc4Ppc44>	Mnu4NlQ4OTB2MkO=
HSC	M4[ycmZ2dmO2aX;uJGF{e2G7	MlPqNlAh\|ryP	MlXoNUBp		MnK1ZYJzd2ejdHXzJJRp\SCmaX\m[ZJmdnSrYXyg[YZn\WO2czDv[kBt\XC2aX6gc5IhSUeHcx?=	NVi1TmxrOjR4MUSxPVk>
EJ	MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjYOVAwQDBizszN	NUfVXINpOjRxNEivO\|IhcA>?		M{H6PYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NUfMN5diOjR3OEewOFk>
EJ	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{POZVUxNzhyIN88US=>	NWLnSpdZPDhiaB?=		MkDPZ4F2e2W\|IGOtdIhie2ViYYLy[ZN1	M2H0WVI1PTh5MES5
EJ	NI\FWlRHfW6ldHnvckBCe3OjeR?=	NGH5Wmk2OC96MDFOwG0>	MXy0PEBp		M{LZU4Rwf26{ZXf1cIF1\XNiYz3NfYMtKGO7Y3zpcmQyNCC\|dYL2bZZqdiCjbnSgWmVITiCneIDy[ZN{cW:wcx?=	MWiyOFU5PzB2OR?=
HepG2	MWDGeY5kfGmxbjDBd5NigQ>?	NV3HO\|d7PTBvNUCwJO69VQ>?	M37SSFYxyqCvaX6=		MVHpcohq[mm2czD0bIUhUUxvNj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSBqVInyO\|A2MSCjbnSgV3RCXDNiKGT5dlcxPSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NXfYN3R2OjR{NEKwOFY>
SGC7901	NWrF[2xkS2WubDDWbYFjcWyrdImgRZN{[Xl?	NXPPR5dQOC1zMECg{txO	NVzQNotFOjRxNEivO\|IhcA>?		Ml63Z4F2e2W\|IHGgd4lodmmoaXPhcpQhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGSxc3Wt[IVx\W6mZX70cJkh[nW2IH7veEB1cW2nLXTldIVv\GWwdHz5	NX7ORVQzOjRzNUGyOVU>
AGS	MVTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MoXFNE0yODBizszN	Mn7YNlQwPDhxN{KgbC=>		MVXjZZV{\XNiYTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh\G:\|ZT3k[ZBmdmSnboTsfUBjfXRibn;0JJRqdWVvZHXw[Y5l\W62bIm=	M1[3clI1OTVzMkW1
SGC7901	NYjwSFk4TnWwY4Tpc44hSXO\|YYm=	M2P0S\|UxKM7:TR?=	MYmyOE81QC95MjDo		M1rCXJRp\SCuZY\lcJMhd2ZicFrBT\|Ih[mWpYX6geI8h\GWlbHnu[UBifCB{NDDodkwh[W6mIILlZo92dmSnZDDheEA4OiCqctMg	MWSyOFE2OTJ3NR?=
AGS	Mo\1SpVv[3Srb36gRZN{[Xl?	MUC1NEDPxE1?	M1rZUlI1NzR6L{eyJIg>		NETTVo51cGVibHX2[Yx{KG:oIIDKRWszKGKnZ3HuJJRwKGSnY3zpcoUh[XRiMkSgbJItKGGwZDDy[YJwfW6mZXSgZZQhPzJiaINCpC=>	M{TZRVI1OTVzMkW1
SGC7901	MnPTSpVv[3Srb36gRZN{[Xl?	NGnYRWM2OCEQvF2=	MXeyOE81QC95MjDo		MlKweIhmKGO7dH;wcIF{dWmlIHzvZ4FtcXqjdHnvckBw\iCySlHLNkApUkGNMjDwbI9{eGixconsZZRm\CCjdDDy[ZNq\HWnczDUfZIyODB5IHHu[EBVgXJzMEC4LUBl\WO{ZXHz[YQh[W[2ZYKgRWc1QTBidILlZZRu\W62IH\vdkAzPCCjbnSgOFghcHJuIHL1eEB{fGG{dHXkJJRwKHKnYn;1coQh[XRiN{KgbJI>	NXXWNpp2OjRzNUGyOVU>
AGS	NX7zSpNQTnWwY4Tpc44hSXO\|YYm=	NGPTSos2OCEQvF2=	NWfHd3ZXOjRxNEivO\|IhcA>?		NUnVdFNYfGinIHP5eI9xdGG\|bXnjJIxw[2GuaYrheIlwdiCxZjDwTmFMOiBqSlHLNkBxcG:\|cHjvdplt[XSnZDDheEBz\XOrZIXld{BVgXJzMEC3JIFv\CCWeYKxNFA5MSCmZXPy[YF{\WRiYX\0[ZIhSUd2OUCgeJJm[XSvZX70JIZweiB{NDDhcoQhPDhiaIKsJIJ2fCC\|dHHyeIVlKHSxIILlZo92dmRiYYSgO\|IhcHJ?	MX:yOFE2OTJ3NR?=
MC3T3-E1	Mn;HSpVv[3Srb36gRZN{[Xl?	MX21NEDPxE1?	NYjlcJFJPCCq		MW\pcohq[mm2czDIV2UucW6mdXPl[EBDVVB5IHHu[EBIUFJicILveIVqdiCneIDy[ZN{cW:wwrC=	NF7aenozOzh5N{ezOC=>
7TD1-DXM	NInhWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnXZ\|YyOCEQvF2=	MnLJO\|IhcA>?	MmrOSG1UVw>?	MYLpcohq[mm2czDj[YxtKGe{b4f0bC=>	MYqyN\|g4OTF3OR?=
7TD1-WD-90	NYfkeYxqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUm1bm1oOTBizszN	NYPQdJFoPzJiaB?=	Mlu3SG1UVw>?	NFXWTodqdmirYnn0d{Bk\WyuIHfyc5d1cA>?	MmfRNlM5PzFzNUm=
7TD1-DXM	MlnlRZBweHSxc3nzJGF{e2G7	NIDkRmw2OCEQvF2=	MnHqOFghcA>?	MkXRSG1UVw>?	MYPpcoR2[2W\|IHHwc5B1d3Orcx?=	MXiyN\|g4OTF3OR?=
7TD1-WD-90	NGLmV2dCeG:ydH;zbZMhSXO\|YYm=	NEPKfmM2OCEQvF2=	NXnKXXhsPDhiaB?=	MYPEUXNQ	M4DRV4lv\HWlZYOgZZBweHSxc3nz	NITLUYczOzh5MUG1PS=>
7TD1-WD-90	M4rzemZ2dmO2aX;uJGF{e2G7	NVK2XFk2PTBizszN	M4rKcFYhcA>?	MVLEUXNQ	NUP5NHV7e2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEqDS{KgZY5lKHCqb4PwbI9zgWyjdHnvckBw\iCVVFHUNy=>	NITF[pEzOzh5MUG1PS=>
HepG2	MnfRSpVv[3Srb36gRZN{[Xl?	MVmxNFAh\|ryP	NFjsVVcyOi9{NDDo		NYC1cIVjcW6qaXLpeJMhW1SDVEOgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:w	M3PxfVI{QDN4NECw
RAW264.7	NIPPPVBHfW6ldHnvckBCe3OjeR?=	M3Xm[FUxyqEQvF5CpC=>	MlnNNlQwPDhiaB?=		MnLpd5VxeHKnc4Pld{BTSU6NTD3pcoR2[2WmIH;zeIVw[2yjc4Tv[4Vv\XOrcx?=	MWWyN\|Y3PTBzOB?=
RAW264.7	MoXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHFXGcxNTVywrFOwG3DqA>?	NV76V\|N{PDkEoHi=		M4DEOYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wt[IVx\W6mZX70cJk>	NIXMNYczOzZ4NUCxPC=>
RAW264.7	NWXLOFlTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TFfFAuPTEEoN88UeKh	M4HJdFQ5yqCq		M4TET4NifXOnczDhckBienKnc4Sgc4YhWkGZMk[0Mlch[2WubIOgZZQhfGinIFewM2cyKHCqYYPlJI9nKHSqZTDj[YxtKGO7Y3zl	NYfBRZBjOjN4NkWwNVg>
RAW264.7	NELGZoZHfW6ldHnvckBCe3OjeR?=	NV\teGpQPTEEoN88US=>	NUfncZFvOjRxNEigbC=>		MWPpcohq[mm2czDSRW5MVC2rbnT1Z4VlKE6IQWTjNUBmgHC{ZYPzbY9vKGGwZDDwbI9{eGixconsZZRqd25ib3[gV4VzPzJ5U2TBWFM>	NUnEZZFbOjN4NkWwNVg>
A549	NI\IOJZHfW6ldHnvckBCe3OjeR?=	MVuyNE81OCEQvF2=	MkTlNlAhcA>?		MYOyNEDPxE1iQVe0PVAhe3WycILld5NmeyC2aHWgdoFlcWG2aX;uMYlv\HWlZXSgbY53[XOrb36gc4YhSTV2OTDj[Yxtew>?	MYKyN\|YzODF7MR?=
A549	M3fic2Z2dmO2aX;uJGF{e2G7	M2LnUlExNzJyL{SwJO69VQ>?	NUTy[ZlqOjRiaB?=		NX7jT2k6e3WycILld5NmeyC2aHWgdoFlcWG2aX;uMYlv\HWlZXSg[YxmfmG2aX;uJI9nKF[HR1dCpC=>	NWrBfYtIOjN4MkCxPVE>
HUVECs	NF7UOpVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	MnnWNlAhyrWP	NIT6SXo1KGh?		MV7heJRmdnWjdHXzJGgzVzJvaX7keYNm\CClZXzsJJNpemmwa3Hn[UBidmRiaX3wdo93\WRidHjlJIF1fGGlaH3lcpQhemG2ZTDv[kB1cGViY3XscJM>	MWGyN\|Q5Ozl2Nh?=
HUVECs	MlP4RZBweHSxc3nzJGF{e2G7	Ml30NlAhyrWP	NXHRdVdWPCCq		NX:1R3BFe2mpbnnmbYNidnSueTDk[YNz\WG\|ZYOgeIhmKGOnbHygZZBweHSxdHnjJIlv\GW6	MYqyN\|Q5Ozl2Nh?=
BV-2	MnLwSpVv[3Srb36gRZN{[Xl?	MoLQNlAhyrWP	NUCzbGlKOTZiaB?=		NUf0c4h[cW6qaXLpeJMhVFCVLXnu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJJdqfGhiYXztc5N1KGOxbYDs[ZRmdHliZHntbY5qe2inZDDpUm9UKGW6cILld5Nqd25?	NF\PSpYzOzJ\|NkO3NC=>
NRK-52E	NXnyOXNZTnWwY4Tpc44hSXO\|YYm=	MXy1xsDPxE1?	NV3uWY5JOzEEoH3pci=>		NXzHc5l[[XS2ZX71ZZRmeyCDbnetLFHjiJN5KT3pcohq[mm2ZXSgWGdHNc7{MTDtVm5CKGG2IEG2xsBpyqB?	MVKyN\|E4PDd3Nx?=
SW620	MnntSpVv[3Srb36gRZN{[Xl?	NVvtNWk{OjBiwsXN	MnjBNU83KGh?		NE\LOGRqdmirYnn0d{BxNVOWQWSzJIFkfGm4YYTpc44>	M4i2UlI{OTFyNkK1
RPE	NIL2fG9HfW6ldHnvckBCe3OjeR?=	NF;Kb40{OCEEtV5CpC=>	M1Hue\|MhcA>?		MYXpcohq[mm2czD0bIUhcW6mdXP0bY9vKG:oIICtV3RCXDNiZYjwdoV{e2mxbh?=	MX2yN\|A6PDB4Nx?=
SW1116	NIPuSlZHfW6ldHnvckBCe3OjeR?=	NGP0RoYyODBiwsXNxsA>	NHOzWpUzPC92OD:3NkBp		MmjX[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJGpCUzJiYX7kJJBLSUt{IITpcYUu\GWyZX7k[Y51dHl?	NHP2T\|UzOjB3MEe5NC=>
HT29	NXr3eYVlTnWwY4Tpc44hSXO\|YYm=	NIm3do8yODBiwsXNxsA>	MlvnNlQwPDhxN{KgbC=>		M1H0O4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBLSUt{IHHu[EBxUkGNMjD0bY1mNWSncHXu[IVvfGy7	MXeyNlA2ODd7MB?=
SW1116	MVTGeY5kfGmxbjDBd5NigQ>?	Mlv0NVAxKML3TdMg	NWLG[o1xOjRxNEivO\|IhcA>?		MV;k[YNz\WG\|ZYOgeIhmKHCVVFHUN{Bt\X[nbIOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=>	MX6yNlA2ODd7MB?=
HT29	MVPGeY5kfGmxbjDBd5NigQ>?	Mn7mNVAxKML3TdMg	NG\HdJYzPC92OD:3NkBp		MVfk[YNz\WG\|ZYOgeIhmKHCVVFHUN{Bt\X[nbIOgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=>	M2P3PVIzODVyN{mw
ARPE-19	Mn3TSpVv[3Srb36gRZN{[Xl?	MU[1xsDPxE1?	MkLtN\|DDqG2rbh?=		NIrHUYtqdmirYnn0d{BLSUt{IIDoc5NxcG:{aXzheIlwdg>?	MU[yNVYzODl4Mx?=
HSC-T6	NIXkXndCeG:ydH;zbZMhSXO\|YYm=	MWOxNOKh\|ryP	MX[yxsBpyqB?		NUPESIVzcW6qaXLpeJMhfGinIHHwc5B1d3OrczDv[kBJW0NvVE[gZ4VtdHNiaX7keYNm\CCkeTDDSGU>	NWDMPYlsOjF\|OU[5PVg>
HSC-T6	MXzGeY5kfGmxbjDBd5NigQ>?	MXmxNOKh\|ryP	NYHOZpVbOsLiaNMg		NYfrN3U5cW6qaXLpeJMhfGinIHX4dJJme3Orb37zJI9nKHC\LWPURXQyKGGwZDDCZYQhcW6mdXPl[EBjgSCFRFW=	MY[yNVM6Pjl7OB?=
Hep-2	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHu[mkzPS1zMECg{txO	NILBdWwzPC92OD:3NkBp		MkTNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MXWyNVMxQTR6MR?=
Hep-2	MXnBdI9xfG:\|aYOgRZN{[Xl?	M4jGeFUxKM7:TR?=	NY\qV4lsOjRxNEivO\|IhcA>?		NVzIc4lXcW6mdXPld{Bk\WyuIHHwc5B1d3OrczD0bY1mKGSncHXu[IVvfGy7	NWHkfog5OjF\|MEm0PFE>
Hep-2	NECxcpdHfW6ldHnvckBCe3OjeR?=	MonuOVAh\|ryP	NHrzTZYzPC92OD:3NkBp		MXfpcohq[mm2czDHNUB1dyCVIHPlcIwh[3mlbHWgeJJidnOrdHnvckBidmRiaX7keYNmeyCJMTDj[YxtKGO7Y3zlJIFzemW\|dB?=	MYqyNVMxQTR6MR?=
Hep-2	NVzjXm12TnWwY4Tpc44hSXO\|YYm=	NHXXOFU2OCEQvF2=	NICwPVAzPC92OD:3NkBp		Moro[I94dnKnZ4XsZZRmeyC2aHWgV3RCXDNuIICtV3RCXDNiYX7kJJN2en[rdnnuJJBzd3SnaX6gcIV3\Wy\|	NGXyOoYzOTNyOUS4NS=>
KF8	Mm\YSpVv[3Srb36gRZN{[Xl?	NV\4[FBtOTEEoN88UeKh	MV6xxsBp	NYTI[GF6TE2VT9Mg	MWDpcohq[mm2czDJUE0{Oy2rbnT1Z4VlKE6ILd86RkBi[3SrdnH0bY9v	NY\CXmdPOjB7NECwOFU>
KF8	MmLvSpVv[3Srb36gRZN{[Xl?	MYOxNOKh\|ryPwrC=	MojjNeKhcMLi	NWHjeml2TE2VT9Mg	M12yS4lvcGmkaYTzJGlNNTN\|LXnu[JVk\WRiSd86Ru6yKGSnZ4Lh[IF1cW:wIHHu[EBPTi4QulKgZYN1cX[jdHnvci=>	MWGyNFk1ODB2NR?=
HEL	MXHGeY5kfGmxbjDBd5NigQ>?	NFvsWnEyODEEoN88US=>	MkHCNVIuPzJiaB?=		MlvWbY5pcWKrdIOgeIhmKGyndnXsJI9nKHBvSlHLNkwhUkGNMh?=	MorsNlA3OjFyNkG=
HEL	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjlNVAxyqEQvF2=	Mlz2NE02KGR?		M{nBOpJm\HWlZYOg[5Jwf3SqIH;mJGpCUzKYNkG3Sk1mgHC{ZYPzbY5oKEiHTDDj[Yxtew>?	NInLXoszODZ{MUC2NS=>
A-172	M2XIfmZ2dmO2aX;uJGF{e2G7	MX61NE8yODEEoN88US=>	M4L6R\|Q5KGh?		M4DWXpJm\HWlZYOgeIhmKGyndnXsd{Bw\iClb37zeIl1fXSrdnXsfUBi[3SrdnH0[YQhW1SDVEOgbY4h[SC2aX3lMYRmeGWwZHXueEBidmRiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	MYWyNFU5QTV{NR?=
MZ-18	NF\IO\|RHfW6ldHnvckBCe3OjeR?=	M3nlT\|UxNzFyMNMg{txO	M17ZRVQ5KGh?		MULy[YR2[2W\|IITo[UBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJHNVSVR\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgZY5lKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	NFPVSZozODV6OUWyOS=>
MZ-54	M1XHSWZ2dmO2aX;uJGF{e2G7	NFLMV482OC9zMEFCpO69VQ>?	NV32e\|g6PDhiaB?=		NXjFV3ZtemWmdXPld{B1cGVibHX2[Yx{KG:oIHPvcpN1cXS3dHn2[Yx6KGGldHn2ZZRm\CCVVFHUN{BqdiCjIITpcYUu\GWyZX7k[Y51KGGwZDDkc5NmNWSncHXu[IVvfCCoYYPobY9v	Mo[xNlA2QDl3MkW=
MZ-256	NE\4dJBHfW6ldHnvckBCe3OjeR?=	NWWzPXlUPTBxMUCwxsDPxE1?	M4PQbVQ5KGh?		MYHy[YR2[2W\|IITo[UBt\X[nbIOgc4Yh[2:wc4TpeJV1cX[nbImgZYN1cX[jdHXkJHNVSVR\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgZY5lKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	NITyRmczODV6OUWyOS=>
MZ-304	NEO5bo5HfW6ldHnvckBCe3OjeR?=	NUD0b21XPTBxMUCwxsDPxE1?	MknTOFghcA>?		MoCydoVlfWOnczD0bIUhdGW4ZXzzJI9nKGOxboP0bZR2fGm4ZXz5JIFkfGm4YYTl[EBUXEGWMzDpckBiKHSrbXWt[IVx\W6mZX70JIFv\CCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	NWHrdXBYOjB3OEm1NlU>
A-172	NVW2fGpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvPOVAwOTBywrFOwG0>	MYq0PEBp		MofGcIVi\HNidH:gZUB{fGG2aYP0bYNidGy7IIPp[45q\mmlYX70JJJm\HWldHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25ib4\ldkBiKHSrbXWgdIVzcW:mIH;mJFQ5yqCq	M2TP[\|IxPTh7NUK1
MZ-18	NXPP[\|dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLLOnBOPTBxMUCwxsDPxE1?	M3q1WlQ5KGh?		NXizW4UxdGWjZIOgeI8h[SC\|dHH0bZN1cWOjbHz5JJNq\26rZnnjZY51KHKnZIXjeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gc5ZmeiCjIITpcYUheGW{aX;kJI9nKDR6wrDo	NFq0eVIzODV6OUWyOS=>
MZ-54	M3HNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLJOVAwOTBywrFOwG0>	NELwOpY1QCCq		MY\s[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh?	Moj5NlA2QDl3MkW=
MZ-256	M2\wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LPNFUxNzFyMNMg{txO	MWS0PEBp		M4fxRoxm[WS\|IITvJIEhe3SjdHnzeIlk[WyueTDzbYdvcW[rY3HueEBz\WS3Y4Tpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIH;2[ZIh[SC2aX3lJJBmemmxZDDv[kA1QMLiaB?=	M3XDfVIxPTh7NUK1
MZ-304	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzTOVAwOTBywrFOwG0>	NH\GUVE1QCCq		MWXs[YFleyC2bzDhJJN1[XSrc4TpZ4FtdHlic3nncolncWOjboSgdoVlfWO2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiCxdnXyJIEhfGmvZTDw[ZJqd2Rib3[gOFjDqGh?	MnLmNlA2QDl3MkW=
A-172	M{nTbGZ2dmO2aX;uJGF{e2G7	NGX0[G82OC9zMEFCpO69VQ>?	M4[zblQ5KGh?		NV;IcW9KcW6qaXLpeJMhdWmpcnH0bY9v	MXGyNFU5QTV{NR?=
MZ-18	NIG4ZolHfW6ldHnvckBCe3OjeR?=	MUS1NE8yODEEoN88US=>	MnrIOFghcA>?		M1uxU4lvcGmkaYTzJI1q\3KjdHnvci=>	MX6yNFU5QTV{NR?=
MZ-54	MUPGeY5kfGmxbjDBd5NigQ>?	Mme0OVAwOTBywrFOwG0>	NIG2c\|E1QCCq		MmnFbY5pcWKrdIOgcYloemG2aX;u	MnXhNlA2QDl3MkW=
MZ-256	MYPGeY5kfGmxbjDBd5NigQ>?	MXW1NE8yODEEoN88US=>	M13xdlQ5KGh?		MlrnbY5pcWKrdIOgcYloemG2aX;u	NXnD[5hROjB3OEm1NlU>
MZ-304	MWXGeY5kfGmxbjDBd5NigQ>?	NF7wXnI2OC9zMEFCpO69VQ>?	NYW3XotvPDhiaB?=		NYnZfnV2cW6qaXLpeJMhdWmpcnH0bY9v	MUCyNFU5QTV{NR?=
A-172	NH35NXZHfW6ldHnvckBCe3OjeR?=	NEe2XIQyODEEoN88US=>	NHO5XGw1QCCq		NVPwdXZ{cW6qaXLpeJMhcW64YYPpc44>	NXHld49uOjB3OEm1NlU>
MZ-18	MmC1SpVv[3Srb36gRZN{[Xl?	MYCxNFDDqM7:TR?=	NIDVPXk1QCCq		MkTGbY5pcWKrdIOgbY53[XOrb36=	MXmyNFU5QTV{NR?=
MZ-54	M{XOWGZ2dmO2aX;uJGF{e2G7	MUWxNFDDqM7:TR?=	M3yz[VQ5KGh?		NGfnWVVqdmirYnn0d{Bqdn[jc3nvci=>	MYWyNFU5QTV{NR?=
MZ-256	MV\GeY5kfGmxbjDBd5NigQ>?	MVOxNFDDqM7:TR?=	MY[0PEBp		MlL0bY5pcWKrdIOgbY53[XOrb36=	M2TveVIxPTh7NUK1
MZ-304	NX;4bVJlTnWwY4Tpc44hSXO\|YYm=	NInlVZQyODEEoN88US=>	Ml\xOFghcA>?		M{\pdolvcGmkaYTzJIlvfmG\|aX;u	NVXwfGFDOjB3OEm1NlU>
A-172	NG\SO5RHfW6ldHnvckBCe3OjeR?=	MWG1NE8yODEEoN88US=>	M32yXVQ5KGh?		M1X1NZJm\HWlZYOgeJJidnOlcnnweIlwdiCxZjDNUXAh\2WwZYOgZY5lKHKnZIXj[ZMh\W68eX3heIlkKGGldHn2bZR6KG:oIF3NVJM>	M2\O[FIxPTh7NUK1
MZ-18	M4m0O2Z2dmO2aX;uJGF{e2G7	MUO1NE8yODEEoN88US=>	M3\nTlQ5KGh?		MV3y[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	M4LRc\|IxPTh7NUK1
MZ-54	MXTGeY5kfGmxbjDBd5NigQ>?	M13FUlUxNzFyMNMg{txO	NEjKTXA1QCCq		MVny[YR2[2W\|IITyZY5{[3KrcITpc44hd2ZiTV3QJIdmdmW\|IHHu[EBz\WS3Y3XzJIVvgnmvYYTpZ{Bi[3Srdnn0fUBw\iCPTWDz	M{L6VVIxPTh7NUK1
MZ-256	Mn;5SpVv[3Srb36gRZN{[Xl?	NVr1TopTPTBxMUCwxsDPxE1?	NV;IPYY4PDhiaB?=		NGn3flJz\WS3Y3XzJJRz[W6\|Y4LpdJRqd25ib3[gUW1RKGenbnXzJIFv\CC{ZXT1Z4V{KGWweontZZRq[yCjY4Tpeol1gSCxZjDNUXB{	MVWyNFU5QTV{NR?=
MZ-304	NVLqOZVXTnWwY4Tpc44hSXO\|YYm=	M1vhUFUxNzFyMNMg{txO	MYC0PEBp		NXnFT2tUemWmdXPld{B1emGwc3PybZB1cW:wIH;mJG1OWCCpZX7ld{BidmRicnXkeYNmeyCnbor5cYF1cWNiYXP0bZZqfHlib3[gUW1Rew>?	MnTyNlA2QDl3MkW=
SW1990	NFP0[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrLVIYzOCEQvF2=	NFX1eYEzPC92OD:3NkBp		Ml;FbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	NHex[YozODR6Mki1PC=>
SW1990	M3[4UmZ2dmO2aX;uJGF{e2G7	MkPKNlAh\|ryP	M3TYUFI1KGh?		Ml\Z[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG1OWC1{IHHu[EBXTUeIIH3SUmF{	MlHQNlA1QDJ6NUi=
SW1990	M33udmZ2dmO2aX;uJGF{e2G7	MUGyNEDPxE1?	M3LLTlI1KGh?		MoDR[IVkemWjc3XzJJRp\SCrboTlcpNqfHlib3[gdE1UfGG2MzDlfJBz\XO\|aX;u	M{nvcFIxPDh{OEW4
SW1990	NUTEOJF{UW64YYPpc44hSXO\|YYm=	MkTMNlAh\|ryP	NFvvWIszPCCq		MYHy[YR2[2W\|IHnueoF{cW:wIH;mJHNYOTl7MDDj[Yxte8Li	NWjQSWhJOjB2OEK4OVg>
THP1	NGnGNWhHfW6ldHnvckBCe3OjeR?=	NFrXWJUyOCC3TR?=	MlnFN\|AhdWmwwrC=		NWjKdm91cW6qaXLpeJMhW1SDVEOgeJlzd3OrbnWgdIhwe3Cqb4L5cIF1cW:wIHL5JI93\XJiNkCl	NYPNOmNZOjB\|OUO2PVA>
BMMC	NF;qOpdHfW6ldHnvckBCe3OjeR?=	MYGwMVExKM7:TR?=	MmLPNVXDqG2rbh?=		NXH4bXZKcW6qaXLpeJMhVFSFNNMgdoVt\WG\|ZTDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36ge4l1cCCwZXHyJINwdXCuZYTlJIlvcGmkaYTpc44h[XRiY3;uZ4VvfHKjdHnvcpMh6qn-MUFCpO69VQ>?	NVjMO\|BmOTl6M{W4OFU>
A549	NVztRoR[TnWwY4Tpc44hSXO\|YYm=	NI[5Zo8yPSEQvH2=	NUe1SYRPOSCq		MUHpcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKFOWQWSxJI9vKHS7cn;zbY5mKDdyMTD3ZZMh\GW2ZXP0[YQhOTVibXnuJIFnfGW{IGPQSUBDKHS{ZXH0cYVvfA>?	M2i0OlE6QDBzNk[1
OVCAR-3	NFr4PJNHfW6ldHnvckBCe3OjeR?=	M4rSVFExKHWP	M1nxRVEhcA>?		M4\XcYlvcGmkaYTzJGxRSS2rbnT1Z4VlKFOWQWSzJJBpd3OyaH;yfYxifGmxbh?=	NF[wenIyQTZ2N{O2Ny=>
PA-1	MVvGeY5kfGmxbjDBd5NigQ>?	NHnNcYQyOCC3TR?=	NV\2NYY3OSCq		MYDpcohq[mm2czDMVGEucW6mdXPl[EBUXEGWMzDwbI9{eGixconsZZRqd25?	M{XzUlE6PjR5M{[z
OVCAR-3	MWTGeY5kfGmxbjDBd5NigQ>?	NVrmeVV4OTBidV2=	MUCxJIg>		M4m5W4lvcGmkaYTzJEBNWEFvaX7keYNm\CCxdnHybYFvKGOjbnPldkBk\WyuIH3veIltcXS7	NYC1bmZ3OTl4NEezOlM>
PA-1	NGTVVm5HfW6ldHnvckBCe3OjeR?=	M2WyU\|ExKHWP	MVuxJIg>		NVO3WJF6cW6qaXLpeJMhKEySQT3pcoR2[2WmIH;2ZZJq[W5iY3HuZ4VzKGOnbHygcY91cWyrdIm=	NWHaPXRvOTl4NEezOlM>
Jurkat	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmewOVAh\|ryP	NGftO5ozPC92OD:3NkBp		NEPadZRmdmijbnPld{BVWkGLTD3pcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44>	MUOxPVU3PDh7MR?=
SUPT1	MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXS1NEDPxE1?	M2HRfVI1NzR6L{eyJIg>		NGfkbHNmdmijbnPld{BVWkGLTD3pcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44>	NXe3TIhYOTl3NkS4PVE>
Jurkat	M2\wT2Fxd3C2b4Ppd{BCe3OjeR?=	MWG1NEDPxE1?	NFO0O\|EzPC92ODDo		M3vhcoVvcGGwY3XzJHRTSUmOLXnu[JVk\XNiY3XscEBieG:ydH;zbZM>	MYexPVU3PDh7MR?=
SUPT1	M4i0SmFxd3C2b4Ppd{BCe3OjeR?=	MWS1NEDPxE1?	NVLV[ItROjRxNEigbC=>		Mluy[Y5p[W6lZYOgWHJCUUxvaX7keYNmeyClZXzsJIFxd3C2b4Ppdy=>	MUexPVU3PDh7MR?=

... Click to View More Cell Line Experimental Data

In vivo

Administration of AG-490 drastically reduces the numbers of CD45⁺ and HLA-DR⁺ cells from 48 % and 46% in bone marrow of untreated mice, as well as 38% and 22% in the spleen of untreated mice to undetectale levels. ^[2] In vivo administration of AG-490 causes murine myeloma tumor cell apoptosis but does not inhibit IL-12-mediated macrophage activation and IFN-γ production by lymphocytes. ^[6] Consistent with the in vitro blocking of JAK2 V617F mutant activity, AG-490 treatment at 0.5 mg/day for 10 days effectively inhibits JAK2 V617F mutant-induced tumorigenesis and tumor cell invasion in nude mice. ^[8] Combined therapy with AG-490 and IL-12 induces greater antitumor effects than either agent alone in a murine myeloma tumor model. ^[6]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase autophosphorylation: AG-490 is dissolved in DMSO 10%-H₂O-ethanol 45%. Crude membrane extracts (0.125 μg/mL) are preactivated with EGF (20 nM) in 50 mM HEPES buffer, pH 7.6, and 125 mM NaCl, for 15 minutes at 4 °C. Autophosphorylation activity of EGFR or ErbB2 kinase is assayed at 4 °C for 30 seconds in V-shaped 96-well plates. Membrane extracts (8 μL) are added to each well containing reaction mixture (12 μL, 50mM, HEPES, pH 7.4,125 mM NaCl, 12 mM M₈Ac₂, 2 mM MnCl₂, 1 mM NaVO₃, 1 μM ATP, and 1 μCi[γ-³²P]ATP, final concentrations) and increasing concentrations of AG-490 (4 μL). After termination by addition of hot sample buffer, the samples are run on a 6% SDS-polyacrylamide gel electrophoresis minigel, the gels dried, and autoradiography performed during the linear exposure time period. The receptor bands are scanned densitrometrically, and the results analyzed by the Ez-Fit program. For the analysis of autophosphorylation of JAK2, JAK2 is immunoprecipitated by using anti-JAK2 antibody from lysates of G2 cells pretreated for 16 hours with increasing concentrations of AG-490 (0-50 μM). Immune complexes are then immunoblotted with anti-phosphotyrosine antibody. A dose-dependent inhibition of in vitro kinase activity is demonstrated by assessing JAK2 autophosphorylation.
Cell Research: ^[2]	- Collapse Cell lines: Pre-B ALL Concentrations: Dissolved in DMSO, final concentrations ~ 50 μM Incubation Time: 16 hours Method: Cells are exposed to different concentrations of AG-490 for 16 hours. For the determination of cell proliferation, [³H]tymidine (1 μCi) is added 6 hours or more before the cultures are terminated. Cells are then collected and samples counted in a liquid scintillation counter. (Only for Reference)
Animal Research: ^[2]	- Collapse Animal Models: SCID mice intravenously injected with ALL cells Dosages: 0.85 mg + 0.5 mg daily Administration: Continuous pump infusion supplemented with daily intraperitoneal injections (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	58 mg/mL (197.07 mM)
	Water	Insoluble
	Ethanol	'''6 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+45% PEG 300+ddH2O For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AG-490 (Tyrphostin B42) SDF

Molecular Weight	294.30
Formula	C₁₇H₁₄N₂O₃
CAS No.	133550-30-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	Zinc02557947
Smiles	C1=CC=C(C=C1)CNC(=O)C(=CC2=CC(=C(C=C2)O)O)C#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to know whether AG490 (S1143) goes to CNS through BBB, or not?
Answer:
AG-490 can go through the BBB. You can see this reference: http://bloodjournal.hematologylibrary.org/content/111/4/2062.full.html.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
Most Potent EGFR Inhibitor

Afatinib (BIBW2992) : EGFR(wt), IC50=0.5 nM; EGFR(L858R), IC50=0.4 nM; EGFR(L858R/T790M), IC50=10 nM; HER2, IC50=14 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

Choose Your Country or Region

By Signaling Pathways

By product type

AG-490 (Tyrphostin B42)